{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:00:04Z","timestamp":1780999204434,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07825-2","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:35:02Z","timestamp":1773815702000},"page":"4968-4976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The diagnostic value of [18F]F-NOTA-FAPI PET\/CT in suspected recurrent ovarian cancer with CA125 dynamic increase level but negative conventional imaging findings"],"prefix":"10.1007","volume":"53","author":[{"given":"Shuai","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"7825_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u2009\u2212\u200949.","DOI":"10.3322\/caac.21660"},{"key":"7825_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115:1234\u201344.","journal-title":"Cancer"},{"key":"7825_CR3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(07)70273-5","volume":"8","author":"TI Goonewardene","year":"2007","unstructured":"Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA125 concentrations. Lancet Oncol. 2007;8:813\u201321.","journal-title":"Lancet Oncol"},{"key":"7825_CR4","doi-asserted-by":"crossref","unstructured":"Stephanie Lheureux,Charlie Gourley,Ignace Vergote,Amit M Oza. Epithelial ovarian cancer. Lancet. 2019;393:1240-53.","DOI":"10.1016\/S0140-6736(18)32552-2"},{"key":"7825_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.medcli.2017.11.019","volume":"151","author":"A Palomar Mu\u00f1oz","year":"2018","unstructured":"Palomar Mu\u00f1oz A, Cordero Garc\u00eda JM, Talavera Rubio P, Garc\u00eda Vicente AM, Gonz\u00e1lez Garc\u00eda B, Bell\u00f3n Guardia ME, et al. Usefulness of CA125 and its kinetic parameters and positron emission tomography\/computed tomography (PET\/CT) with fluorodeoxyglucose ([(18)F] FDG) in the detection of recurrent ovarian cancer. Med Clin (Barc). 2018;151:97\u2013102.","journal-title":"Med Clin (Barc)"},{"key":"7825_CR6","doi-asserted-by":"crossref","unstructured":"Liu s, Feng z, Xu x, et al. Head-to-head comparison of [(18)F]-FDG and [(68) Ga]-DOTA-FAPI-04 PET\/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer. Eur J Nucl Med Mol Imaging. 2023;50:1521-31.","DOI":"10.1007\/s00259-022-06096-x"},{"key":"7825_CR7","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1007\/s00259-023-06369-z","volume":"50","author":"J Chen","year":"2023","unstructured":"Chen J, Xu K, Li C, Li CJ, Tian YL, Li L, et al. [(68)Ga]Ga-FAPI-04 PET\/CT in the evaluation of epithelial ovarian cancer: comparison with [(18)F]F-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2023;50:4064\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7825_CR8","first-page":"55","volume":"39","author":"YN Liu","year":"2024","unstructured":"Liu YN, Chen XS, Jing FL, Zhao XM, Zhang ZQ, Zhang JM, et al. Feasibility of one-day PET\/CT scanning protocol with (68)Ga-DOTA-FAPI-04 and (18)F-FDG for the detection of ovarian cancer recurrence and metastasis. Cancer Biother Radiopharm. 2024;39:55\u201363.","journal-title":"Cancer Biother Radiopharm"},{"key":"7825_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/RLU.0000000000004656","volume":"48","author":"GF Sun","year":"2023","unstructured":"Sun GF, Zou RY, Yao LQ, Zuo CJ. 68Ga-FAPI-04 PET\/MR versus 18F-FDG PET\/CT in the detection of ovarian cancer. Clin Nucl Med. 2023;48:525\u20137.","journal-title":"Clin Nucl Med"},{"key":"7825_CR10","doi-asserted-by":"crossref","unstructured":"Xi Y, Sun LL, Che XX, Huang XY, Liu H, Wang Q, et al. A comparative study of [(68)Ga]Ga-FAPI-04 PET\/MR and [(18)F]FDG PET\/CT in the diagnostic accuracy and resectability prediction of ovarian cancer. Eur J Nucl Med Mol Imaging. 2023;50:2885-98.","DOI":"10.1007\/s00259-023-06235-y"},{"key":"7825_CR11","doi-asserted-by":"crossref","unstructured":"Bian L, Liu X, Wang X, Sun Y, Du X, Gu B, et al. Preclinical and First-In-Human Imaging of Novel [(18)F]F-FAPI-FUSCC-07 Tracer: Comparative Prospective Study with [(18)F]F-FAPI-42 and [(18)F]F-FAPI-74. Mol Pharm. 2025;22:1624-32.","DOI":"10.1021\/acs.molpharmaceut.4c01360"},{"key":"7825_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","volume":"90","author":"SM Eisenkop","year":"2003","unstructured":"Eisenkop SM, Spirtos NM, Friedman RL, Lin W-C, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390\u20136.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"7825_CR13","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.21037\/qims-20-784","volume":"11","author":"Z Feng","year":"2021","unstructured":"Feng Z, Liu S, Ju X, Chen X, Li R, Bi R, et al. Diagnostic accuracy of (18)F-FDG PET\/CT scan for peritoneal metastases in advanced ovarian cancer. Quant Imaging Med Surg. 2021;11(8):3392\u20138.","journal-title":"Quant Imaging Med Surg"},{"issue":"2","key":"7825_CR14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","volume":"306","author":"Y Mori","year":"2023","unstructured":"Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease. Radiology. 2023;306(2):e220749.","journal-title":"Radiology"},{"key":"7825_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2025.05.067","volume":"32","author":"C Jiang","year":"2025","unstructured":"Jiang C, Zheng K, Zhang Y, Peng X, Yang J, Ye H, et al. Usefulness of [(18)F]FAPI-04 and [(18)F]FDG PET\/CT for the detection of peritoneal carcinomatosis: a comparative study. Acad Radiol. 2025;32:5897\u2009\u2212\u2009906.","journal-title":"Acad Radiol"},{"key":"7825_CR16","doi-asserted-by":"crossref","unstructured":"16. Wu M, Hao B, Chen Z, Xia T, Chen H, Chen Q, et al. Comparative analysis of (68)Ga-FAPI-46 PET\/CT and (18)F-FDG PET\/CT in advanced epithelial ovarian cancer: implications for preoperative scoring and treatment planning. Eur J Nucl Med Mol Imaging. 2026. Online ahead of print.","DOI":"10.1007\/s00259-025-07721-1"},{"key":"7825_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/RLU.0000000000005871","volume":"50","author":"M Prochiner","year":"2025","unstructured":"Prochiner M, Hinterberger A, W\u00e4ngler B, Marm\u00e9 F, Grawe F. [68Ga]Ga-FAPI-46 PET\/MRT unveils lymph node metastases and changes treatment strategy in recurrent advanced high-grade serous ovarian carcinoma patient. Clin Nucl Med. 2025;50:873\u20134.","journal-title":"Clin Nucl Med"},{"key":"7825_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/bjs.10989","volume":"106","author":"I van \u2019t Sant","year":"2019","unstructured":"van \u2019t Sant I, van Eden WJ, Engbersen MP, et al. Diffusion-weighted MRI assessment of the peritoneal cancer index before cytoreductive surgery. Br J Surg. 2019;106:491\u20138.","journal-title":"Br J Surg"},{"key":"7825_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ygyno.2012.12.024","volume":"129","author":"T Levy","year":"2012","unstructured":"Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol. 2012;129:165\u20138.","journal-title":"Gynecol Oncol"},{"key":"7825_CR20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.ejca.2010.02.012","volume":"46","author":"L Han","year":"2010","unstructured":"Han L, Karavasilis V, Hagen T, Nicum S, Thomas K, Harrison M, et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur J Cancer. 2010;46:1359\u201364.","journal-title":"Eur J Cancer"},{"key":"7825_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-5-11","volume":"22","author":"E Varughese","year":"2012","unstructured":"Varughese E, Kondalsamy-Chennakesavan S, Obermair A. The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2012;22:11.","journal-title":"J Ovarian Res"},{"key":"7825_CR22","doi-asserted-by":"crossref","unstructured":"Caner Civan, Duygu Has Simsek, Emine Goknur Isik, Yasemin Sanli, Serkan Kuyumcu. FAPI-Negative FDG-Avid Metastatic Relapse of Breast Cancer on PET\/CT. Clin Nucl Med. 2023;48:e380-1.","DOI":"10.1097\/RLU.0000000000004704"},{"key":"7825_CR23","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1097\/RLU.0000000000005586","volume":"50","author":"M Bentestuen","year":"2025","unstructured":"Bentestuen M, Sylvest C, Frandsen AP, Zacho HD. Ovarian clear cell adenocarcinoma with low 68Ga-FAPI-46 and low 18F-FDG uptake on PET\/CT: a case report. Clin Nucl Med. 2025;50:e178-9.","journal-title":"Clin Nucl Med"},{"key":"7825_CR24","doi-asserted-by":"crossref","unstructured":"24. Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul Peerapon, Chotipanich Chanisa, et al. Intense 68Ga FAPI-46 activity in lesions of recurrent ovarian clear cell carcinoma that were negative on FDG PET\/CT study. Clin Nucl Med. 2022;47:e210-2.","DOI":"10.1097\/RLU.0000000000003975"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07825-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:21:42Z","timestamp":1780996902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7825"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07825-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Fudan University Shanghai Cancer Center. Informed consent was not applicable because of retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because of retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}